{"title":"The discussion on the differences in immune microenvironment between low-risk and high-risk myelodysplastic syndromes and acute myeloid leukemia.","authors":"Yinglong Wang, Xingdong Xiao, Hanxue Zheng, Jun Bai, Lijuan Li, Liansheng Zhang","doi":"10.1080/10428194.2025.2549519","DOIUrl":"https://doi.org/10.1080/10428194.2025.2549519","url":null,"abstract":"<p><p>This review aims to examine differences in the immune microenvironment between low-risk and high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Furthermore, it explores the impact of immune cell imbalance, abnormal cytokine levels, and stromal cell impairment on disease progression and prognosis. Additionally, the review analyzes the immune mechanisms underlying the transformation of high-risk MDS to AML. These findings provide valuable insights for both prognostic stratification of MDS by means of immune markers and the development of targeted therapies for AML.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-16"},"PeriodicalIF":2.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xenia Parisi, Anindita Ghosh, Guilin Tang, Jeffrey L Jorgensen, L Jeffrey Medeiros
{"title":"Lineage switch of B-lymphoblastic leukemia with <i>KMT2A::AFF1</i> fusion into acute myelomonocytic leukemia under blinatumomab therapy.","authors":"Xenia Parisi, Anindita Ghosh, Guilin Tang, Jeffrey L Jorgensen, L Jeffrey Medeiros","doi":"10.1080/10428194.2025.2549515","DOIUrl":"https://doi.org/10.1080/10428194.2025.2549515","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-4"},"PeriodicalIF":2.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Methods for the analysis of leukemic infiltration within cerebrospinal fluid in acute lymphoblastic leukemia-a systematic review.","authors":"Lavleen Singh, Kanika Rastogi, Amitabh Singh, Shraddhanjali Sathapathy, Venkateswaran K Iyer, Deepali Jain, Rachna Seth","doi":"10.1080/10428194.2025.2550580","DOIUrl":"https://doi.org/10.1080/10428194.2025.2550580","url":null,"abstract":"<p><p>Central nervous system (CNS) involvement in acute lymphoblastic leukemia (ALL) is associated with a poor prognosis, making its accurate detection vital for treatment planning. This systematic review critically examines the role of conventional cytomorphology (CC) and multiparameter flow cytometry (FC) in analyzing cerebrospinal fluid in acute lymphoblastic leukemia cases. While CC remains the gold standard, its sensitivity is limited, particularly in cases with low cell counts. FC offers greater sensitivity in identifying cases of 'occult' CNS disease (FC+/CC-). Pre-analytical variables, such as CSF volume, processing time, and preservation techniques, also influence the accuracy of both methods. Despite the advantages of FC, challenges remain, including the lack of standardized positivity criteria and unclear prognostic implications and management strategies for occult CNS disease (FC+ and CC-). Future research is needed to establish uniform diagnostic guidelines and to assess the clinical relevance of occult CNS disease in ALL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.2,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ke Xu, Zois Mellios, June Hyun, Anna Childerhouse, Jenny O'Nions, Andrew Wilson, Ian Proctor, Sabine Pomplun, Teresa Marafioti, Elisabeth Nacheva, Robert Baker, Rajeev Gupta
{"title":"Diagnosis and management of acute erythroid leukemia (AEL).","authors":"Ke Xu, Zois Mellios, June Hyun, Anna Childerhouse, Jenny O'Nions, Andrew Wilson, Ian Proctor, Sabine Pomplun, Teresa Marafioti, Elisabeth Nacheva, Robert Baker, Rajeev Gupta","doi":"10.1080/10428194.2025.2553166","DOIUrl":"https://doi.org/10.1080/10428194.2025.2553166","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-5"},"PeriodicalIF":2.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leukemia & LymphomaPub Date : 2025-09-01Epub Date: 2025-06-23DOI: 10.1080/10428194.2025.2502805
John Kuruvilla, Dipenkumar Modi, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, Laura Maria Fogliatto, Iara Gonçalves, Jose de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Iryna Kriachok, Naohiro Sekiguchi, Jianxin Lin, Rushdia Yusuf, Patricia Marinello, Pier Luigi Zinzani
{"title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy.","authors":"John Kuruvilla, Dipenkumar Modi, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, Laura Maria Fogliatto, Iara Gonçalves, Jose de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Iryna Kriachok, Naohiro Sekiguchi, Jianxin Lin, Rushdia Yusuf, Patricia Marinello, Pier Luigi Zinzani","doi":"10.1080/10428194.2025.2502805","DOIUrl":"10.1080/10428194.2025.2502805","url":null,"abstract":"<p><strong>This report focuses on a post hoc exploratory analysis of the phase 3 keynote-204 study comparing pembrolizumab and brentuximab vedotin by number of prior lines of therapy in participants with relapsed/refractory (r/r) classical hodgkin lymphoma (chl). of 304 participants randomly assigned (1: </strong>1) to pembrolizumab or brentuximab vedotin, 55 received 1 prior therapy and 249 received ≥2. For 1 prior therapy, median progression-free survival (PFS) at primary analysis (including clinical imaging data after autologous stem cell transplant [auto-SCT]) was 16.4 months with pembrolizumab and 8.4 months with brentuximab vedotin; objective response rate (ORR) was 66.7% and 53.6%. For ≥2 prior therapies, median PFS at primary analysis was 12.6 months with pembrolizumab and 8.2 months with brentuximab vedotin; ORR was 65.3% and 54.4%. Pembrolizumab improved PFS and ORR versus brentuximab vedotin regardless of prior therapies. Data suggest pembrolizumab may be a promising second-line therapy for participants with R/R cHL ineligible for auto-SCT.</p><p><strong>Clinical trial information: </strong>ClinicalTrials.gov, NCT02684292.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1710-1719"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leukemia & LymphomaPub Date : 2025-09-01Epub Date: 2025-06-16DOI: 10.1080/10428194.2025.2518434
Maria Dimou, Maria Karypidou, Aikaterini Bitsani, Marina Belia, Anastasia Kopsaftopoulou, Kalliopi Zerzi, Andreas Kyriakopoulos, Sotirios Sachanas, Ilias Pessach, Aikaterini Kolotsiou, Maria K Angelopoulou, Marina Siakantaris, Theodoros P Vassilakopoulos, Panayiotis Panayiotidis
{"title":"Acalabrutinib resistance in a CLL patient harboring a C515 mutation in the BTK-C isoform.","authors":"Maria Dimou, Maria Karypidou, Aikaterini Bitsani, Marina Belia, Anastasia Kopsaftopoulou, Kalliopi Zerzi, Andreas Kyriakopoulos, Sotirios Sachanas, Ilias Pessach, Aikaterini Kolotsiou, Maria K Angelopoulou, Marina Siakantaris, Theodoros P Vassilakopoulos, Panayiotis Panayiotidis","doi":"10.1080/10428194.2025.2518434","DOIUrl":"10.1080/10428194.2025.2518434","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1764-1765"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leukemia & LymphomaPub Date : 2025-09-01Epub Date: 2025-06-18DOI: 10.1080/10428194.2025.2504719
Durga B Dandamudi, Iwona M Konieczna, Kelly M Calabrese, Monica Wielgos-Bonvallet, Christiaan Kweekel, Elke Gresnigt-van den Heuvel, Ramesh Iyer, Paul Ellis, Luis Rodriguez, Apurvasena Parikh, Tommy Li, Madelon Paauwe, Cormac Cosgrove, Adam S Chervin, Edward B Reilly, Pearlie Epling-Burnette, Edith Szafer-Glusman
{"title":"Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma.","authors":"Durga B Dandamudi, Iwona M Konieczna, Kelly M Calabrese, Monica Wielgos-Bonvallet, Christiaan Kweekel, Elke Gresnigt-van den Heuvel, Ramesh Iyer, Paul Ellis, Luis Rodriguez, Apurvasena Parikh, Tommy Li, Madelon Paauwe, Cormac Cosgrove, Adam S Chervin, Edward B Reilly, Pearlie Epling-Burnette, Edith Szafer-Glusman","doi":"10.1080/10428194.2025.2504719","DOIUrl":"10.1080/10428194.2025.2504719","url":null,"abstract":"<p><p>Epcoritamab, a subcutaneous CD3xCD20 bispecific antibody approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, is being evaluated in regimens containing CD20-targeted monoclonal antibodies (e.g. rituximab plus cylophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]). To demonstrate combinability of epcoritamab with CD20 monoclonal antibodies (mAbs), potential interference of rituximab or obinutuzumab with epcoritamab was investigated. While there was dose-dependent binding interference between CD20 mAbs and epcoritamab through steric hindrance, ex vivo assays using tumor cell lines, R-CHOP-treated patient samples, and an animal model showed this did not impair tumor cell killing. In a pharmacokinetic model, >90% maximal cytotoxicity was predicted after the first full epcoritamab dose in the presence of therapeutic rituximab concentrations due to effective tumor-epcoritamab-T-cell trimer formation. Immunoprofiling of R-CHOP-treated DLBCL patient samples showed emergence of less-differentiated CD8 memory T cells, further supporting the feasibility of the combination in ongoing studies of epcoritamab with rituximab-containing chemoimmunotherapy.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1688-1699"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leukemia & LymphomaPub Date : 2025-09-01Epub Date: 2025-04-21DOI: 10.1080/10428194.2025.2494051
Thomas Davis, Robert Azzopardi, Eric Wong, Andrew Grigg
{"title":"Methotrexate dose modification does not impact on graft vs host disease in allograft patients given thymoglobulin prophylaxis.","authors":"Thomas Davis, Robert Azzopardi, Eric Wong, Andrew Grigg","doi":"10.1080/10428194.2025.2494051","DOIUrl":"10.1080/10428194.2025.2494051","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1731-1734"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leukemia & LymphomaPub Date : 2025-09-01Epub Date: 2025-05-20DOI: 10.1080/10428194.2025.2504154
Gregorio Barilà, Laura Bonaldi, Annalisa Martines, Anna Pascarella, Susanna Vedovato, Cristina Clissa, Laura Pavan, Martina Tinelli, Silvia Nalio, Angela Bonalumi, Antonella Teramo, Giulia Calabretto, Gianpietro Semenzato, Livio Trentin, Mauro Krampera, Alberto Tosetto, Renato Zambello
{"title":"Prognostic stratification of standard risk multiple myeloma defined by revised international scoring system.","authors":"Gregorio Barilà, Laura Bonaldi, Annalisa Martines, Anna Pascarella, Susanna Vedovato, Cristina Clissa, Laura Pavan, Martina Tinelli, Silvia Nalio, Angela Bonalumi, Antonella Teramo, Giulia Calabretto, Gianpietro Semenzato, Livio Trentin, Mauro Krampera, Alberto Tosetto, Renato Zambello","doi":"10.1080/10428194.2025.2504154","DOIUrl":"10.1080/10428194.2025.2504154","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1740-1744"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Risk factors for influenza virus infection in patients with hematological disease.","authors":"Hirotomo Nakashima, Shin-Ichiro Fujiwara, Seina Honda, Ryutaro Tominaga, Daizo Yokoyama, Atsuto Noguchi, Shuka Furuki, Shunsuke Koyama, Rui Murahashi, Takashi Ikeda, Kazuki Hyodo, Shin-Ichiro Kawaguchi, Yumiko Toda, Kento Umino, Daisuke Minakata, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Yoshinobu Kanda","doi":"10.1080/10428194.2025.2495106","DOIUrl":"10.1080/10428194.2025.2495106","url":null,"abstract":"<p><p>Influenza virus infections (IVIs) are an important cause of complications and death in immunocompromised patients, but the incidence and risk factors for IVIs in hematological diseases including benign diseases are not fully understood. We retrospectively investigated IVIs in patients with hematological diseases who visited our hematology outpatient department between 2012 and 2019. In 4,864 outpatients, 81(1.67%) IVIs were identified. The incidence of IVIs was 4.82 (95% confidence interval [CI], 3.85-5.96) per 1,000 person-years, with significantly higher rates in post-allogeneic transplant patients (21.0, 95% CI, 12.8-32.5). Progression to lower respiratory tract infection (LRTI) was observed in 7 (8.6%) of 81 patients with IVIs. In a univariate logistic regression analysis, LTRI was associated with age ≥60 years and moderate to severe chronic GVHD. Patients after hematopoietic stem cell transplantation may be at a higher risk for IVIs. Advanced age exacerbated the effects of IVIs on hematological diseases.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1675-1681"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
